These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Chan FK, Abraham NS, Scheiman JM, Laine L, First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980 [Abstract] [Full Text] [Related]
11. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Fosbøl EL, Køber L, Torp-Pedersen C, Gislason GH. Expert Opin Drug Saf; 2010 Nov; 9(6):893-903. PubMed ID: 20569079 [Abstract] [Full Text] [Related]
12. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. Scheiman JM. Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260 [Abstract] [Full Text] [Related]
13. The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Uzan A. Expert Opin Emerg Drugs; 2005 Nov; 10(4):687-8. PubMed ID: 16262557 [Abstract] [Full Text] [Related]
14. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications. Pascucci RA. J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181 [Abstract] [Full Text] [Related]
15. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. American Gastroenterological AssociationDepartment of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. melw@uab.edu, Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, Hunt R, Ladabaum U, Lanas A, Paulus H, Regueiro C, Sandler RS, Simon L. Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1082-9. PubMed ID: 16877048 [No Abstract] [Full Text] [Related]
16. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal. Davies NM, Reynolds JK, Undeberg MR, Gates BJ, Ohgami Y, Vega-Villa KR. Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779 [Abstract] [Full Text] [Related]
17. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Maillard M, Burnier M. Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958 [Abstract] [Full Text] [Related]
18. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Hinz B, Renner B, Brune K. Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610 [Abstract] [Full Text] [Related]
19. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Hermann M, Ruschitzka F. Ann Med; 2007 Oct; 39(1):18-27. PubMed ID: 17364448 [Abstract] [Full Text] [Related]
20. The practice implications of cardiovascular risks in NSAIDs. Hainsworth T. Nurs Times; 2007 Oct; 101(26):26-7. PubMed ID: 16010838 [Abstract] [Full Text] [Related] Page: [Next] [New Search]